It has been another extremely news flow rich fortnight from the biopharmaceutical Corporation focussed on the biology of healing. We have had four separate pieces of news announced on the PBI-4050 programme, and Q3 highlights/results confirming that ProMetic is funded for at least another year and that the GMP manufacturing infrastructure is now in place to deliver revenue north of C$500m. We detail some highlights of the recent news below, and look forward to today’s analyst day which
21 Nov 2016
No let-up in activity as year-end approaches
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
No let-up in activity as year-end approaches
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
21 Nov 2016 -
Author:
Derren Nathan -
Pages:
6
It has been another extremely news flow rich fortnight from the biopharmaceutical Corporation focussed on the biology of healing. We have had four separate pieces of news announced on the PBI-4050 programme, and Q3 highlights/results confirming that ProMetic is funded for at least another year and that the GMP manufacturing infrastructure is now in place to deliver revenue north of C$500m. We detail some highlights of the recent news below, and look forward to today’s analyst day which